Whitehawk Therapeutics Inc
WHWKHealthcare|Biotechnology|US
$3.13
+0.11 (+3.64%)
Tangible Book / Share
$2.21
Cash / Share
$2.29
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07444814 Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Endometrial Cancer, Ovarian Cancer | P1 | Recruiting | 226 | Open-label | HWK-007 |
| NCT07470853 A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | PROC, Platinum Resistant Ovarian Cancer | P1 | Recruiting | 265 | Open-label | HWK-016, MUCIN-16-targeted ADC, Bevacizumab |